<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Stronger Neo-Minophagen C (SNMC) is a glycyrrhizin-containing preparation that is approved in Japan for the treatment of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">hepatic diseases</z:e> and is marketed in Japan, China, Korea, Taiwan, and India </plain></SENT>
<SENT sid="1" pm="."><plain>Glycyrrhizin, a <z:chebi fb="0" ids="35191">triterpene</z:chebi> present in the roots and rhizomes of licorice (Glycyrrhiza glabra) has been shown to have anti-inflammatory, anti-oxidative, and anti-<z:mp ids='MP_0001799'>viral</z:mp> effects </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we demonstrated the marked neuroprotective effects of SNMC in the postischemic rat brain after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="3" pm="."><plain>We used 1 ml/kg of SNMC, which is within the dose range used for the treatment of patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">hepatic disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The administration of SNMC intravenously at 30 minutes before or 30 minutes and 3 hours after MCAO (60 minutes) reduces mean <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes to 27.0±4.2%, 37.1±12.4%, and 67.8±5.8% of that of untreated controls, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>This neuroprotective effect is accompanied by improvements in motor impairment and neurological deficits </plain></SENT>
<SENT sid="6" pm="."><plain>The administration of SNMC is shown to suppress microglia activation and neutrophil infiltration in the postischemic brain </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, SNMC suppresses <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi>-induced <z:chebi fb="95" ids="16301">nitrite</z:chebi> production and proinflammatory cytokine induction in a microglia cell line, BV2 </plain></SENT>
<SENT sid="8" pm="."><plain>This indicates that the neuroprotective effect of SNMC might be due, at least in part, to an anti-inflammatiory effect </plain></SENT>
<SENT sid="9" pm="."><plain>Interestingly, SNMC shows significantly higher neuroprotective potency compared to an equivalent dose of pure glycyrrhizin, in terms of reducing <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and improving neurological deficits </plain></SENT>
<SENT sid="10" pm="."><plain>Together these results indicate that SNMC, a glycyrrhizin-containing preparation developed for <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e>, has a marked neuroprotective function in the postischemic brain via its anti-inflammatory effects </plain></SENT>
</text></document>